Patent 8,178,550 landscape: crystalline Form I monohydrate hydrochloride (Formula I) IP scope, claim coverage, and US freedom-to-operate levers
United States Drug Patent 8,178,550 claims a single chemical entity defined by the stereospecific diazaspiro scaffold and a specific solid-state salt form: crystalline Form I, monohydrate hydrochloride of (5S,8S)-8-[{(1R)-1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4,5]decan-2-one (“Formula I”). The claim set is a typical late-stage solid-form estate: (i) tight XRD identity anchors (one mandatory peak and optional combinatorial peak sets), (ii) spectroscopic identity anchors (IR and Raman peak lists or figures), (iii) thermal fingerprinting (DSC), and (iv) composition/product claims directed to using the claimed solid form.
What patents protect US 8,178,550 crystalline Form I monohydrate hydrochloride salt?
Core protection type: polymorph/solvate/salt solid-form IP plus product-use in compositions.
What is actually claimed: the salt crystal form, not merely the underlying freebase or “any hydrochloride.”
How claim scope is operationalized (the infringement trigger)
- Material scope is limited to the specific crystalline entity: “crystalline Form I monohydrate hydrochloride salt form” of Formula I.
- Identity scope is limited by analytical requirements:
- XRD: peak at 2Θ 21.6 ± 0.2 with lattice spacing 4.11 ± 0.04 as a must-have in claim 1.
- XRD: dependent claims add additional peak combinations at 2Θ 16.1 (5.49 Å), 18.4 (4.83 Å), 23.5 (3.78 Å) with ± tolerances.
- IR: strong peak at 1167 cm⁻1 (must-have in claim 6) plus additional peak combinations including 1693, 1277, 1141, 1130, 1094, 703, 682 cm⁻1.
- Raman: weak peak at 3695 cm⁻1 (must-have in claim 12) plus additional peak combinations including 3690, 3625, 1604, 1032, 997, 724, 616 cm⁻1.
- DSC: at least an endotherm centered at ~101°C.
- Product scope: pharmaceutical composition claims incorporate the Form I monohydrate hydrochloride salt form as the active solid.
Claim-by-claim scope map (US 8,178,550)
Independent claim
- Claim 1: Form I monohydrate hydrochloride salt form defined by XRD identity (must include the 21.6 ± 0.2 / 4.11 ± 0.04 peak).
Dependent claim tiers
- Claims 2–4: broaden Form I identification by requiring additional XRD peaks or a specific peak set including 21.6 strong plus 16.1 / 18.4 / 23.5 depending on the claim.
- Claims 5: Form I monohydrate hydrochloride defined by FIG. 1 (a figure-based XRD fingerprint).
- Claims 6–10: Form I monohydrate defined by IR identity (must include 1167 cm⁻1 in claim 6; additional peak combinations in claims 7–9; exact peak set in claim 10).
- Claims 11: IR defined by FIG. 2.
- Claims 12–16: Form I monohydrate defined by Raman identity (must include 3695 cm⁻1 in claim 12; additional combinations in claims 13–15; exact set in claim 16).
- Claims 17: Raman defined by FIG. 3.
- Claims 18–19: Form I monohydrate defined by DSC fingerprint (endotherm at ~101°C in claim 18; “substantially as shown” in FIG. 4 in claim 19).
Composition claims
- Claims 20–23: pharmaceutical compositions comprising the claimed solid form, with dependence tying the claim basis to:
- Claim 1 (claim 20),
- Claim 6 (claim 21),
- Claim 12 (claim 22),
- Claim 18 (claim 23).
Practical effect: infringement analysis in US 8,178,550 will be driven by whether an accused sample demonstrates the required analytical fingerprint for the claimed solid-state form, particularly the anchor peaks and the required tolerance windows.
What is the strongest claim in 8,178,550 for enforcement leverage?
Answer: Claim 1 is the primary enforcement hook because it is the only independent claim and it has a single defining XRD anchor:
- XRD must show at least a strong peak at 2Θ 21.6 ± 0.2 / 4.11 ± 0.04 (with “crystalline Form I monohydrate hydrochloride salt form” being the claimed product).
Why that matters: a single anchor peak lowers the analytical burden for a patentee compared with claims requiring multiple peaks or multiple orthogonal tests. Dependent claims (2–4) create fallback positions that are more specific and potentially easier to defend against “false positives” (i.e., different solids with a shared partial XRD feature).
Next-best enforcement candidates:
- Claim 6: IR must include 1167 cm⁻1 (strong peak), creating an orthogonal analytical anchor.
- Claim 12: Raman must include 3695 cm⁻1 (weak peak), again orthogonal.
- Claim 18: DSC must show an endotherm centered at ~101°C, adding thermal corroboration.
These create a multi-modal identification approach typical for solid-form patents, allowing enforcement to be framed through whichever analytical dataset is easiest to replicate in court.
How does 8,178,550 define “crystalline Form I monohydrate hydrochloride” using XRD, IR, Raman, and DSC?
Core identity standard is multi-analytical. The specification (not provided here) likely maps how these peaks are measured, but the claim language itself sets the identity constraints.
XRD identity (claims 1–5)
- Anchor (claim 1): at least a strong XRD peak at:
- 2Θ 21.6 ± 0.2
- d-spacing 4.11 ± 0.04 Å
- Additional peak logic (claims 2–4):
- Claim 2: requires at least one additional peak selected from the set:
- 16.1 (5.49 Å), 18.4 (4.83 Å), 23.5 (3.78 Å)
- Claim 3: requires at least two additional peaks from that set
- Claim 4: requires a specific combined set including:
- 16.1 (5.49 Å), 18.4 (4.83 Å), 21.6 strong (4.11 Å), 23.5 (3.78 Å)
- Figure-based claim (claim 5): “as shown in FIG. 1” for the XRD pattern.
IR identity (claims 6–11)
- Anchor (claim 6): strong IR peak at 1167 cm⁻1
- Additional peaks (claims 7–9):
- candidate peaks: 1693, 1277, 1141, 1130, 1094, 703, 682 cm⁻1
- claim 7: at least one additional
- claim 8: at least two additional
- claim 9: at least three additional
- Exact set (claim 10): 1693, 1277, 1167, 682 cm⁻1
- Figure-based claim (claim 11): IR “as shown in FIG. 2”.
Raman identity (claims 12–17)
- Anchor (claim 12): at least a weak Raman peak at 3695 cm⁻1
- Additional peaks (claims 13–15):
- candidate peaks: 3690, 3625, 1604, 1032, 997, 724, 616 cm⁻1
- Exact set (claim 16): 3695, 1032, 997, 724 cm⁻1
- Figure-based claim (claim 17): Raman “substantially as shown in FIG. 3”.
DSC identity (claims 18–19)
- Claim 18: at least an endotherm centered at ~101°C
- Claim 19: DSC “substantially as shown in FIG. 4”.
Enforcement reality for solid-form patents: accused products are rarely “purely asserted” as XRD-only; practitioners often contest whether an analyte is the same polymorph/solvate/salt using orthogonal techniques. Here, the claim drafting anticipates that by giving multiple claim routes.
What formulation patents does 8,178,550 cover: drug product vs active solid?
Answer: 8,178,550 covers compositions that contain the claimed solid form, not necessarily specific dosage forms, excipients, or release mechanisms.
What is claimed in the composition layer
- Claim 20: pharmaceutical composition comprising the Form I monohydrate hydrochloride defined by claim 1.
- Claim 21: pharmaceutical composition comprising the Form I monohydrate hydrochloride defined by claim 6.
- Claim 22: composition comprising the Form I monohydrate hydrochloride defined by claim 12.
- Claim 23: composition comprising the Form I monohydrate hydrochloride defined by claim 18.
Implication: if a generic or follow-on manufacturer uses a different solid form (e.g., different polymorph, anhydrous form, different hydrate level, different salt counterion) they may avoid direct coverage, even if they use the same active compound (Formula I freebase or another salt). If they use the claimed Form I monohydrate hydrochloride, composition claims can capture tablets, capsules, powders, suspensions, and other dosage forms, subject to how “pharmaceutical composition” is construed in the context of the broader patent family.
When does US 8,178,550 lose exclusivity?
No exclusivity loss date can be computed from the claim text alone. Exclusivity and patent expiry depend on:
- application filing date,
- priority chain,
- patent term adjustments,
- any terminal disclaimers,
- whether it is a US patent subject to 20-year term from earliest effective non-provisional filing, and
- any regulatory exclusivity overlays (NCE/505(b)(2) etc.).
Per your constraints, only the information available in the prompt can be used. The prompt does not include the filing/priority/issue dates or regulatory data needed to state an expiry or exclusivity timeline.
What generic entry risks exist for products using the same API but different solid forms?
Answer: the core risk is “accidental capture” if the manufacturing process yields the same Form I monohydrate hydrochloride as the claimed identity, even if the generic intends otherwise.
How manufacturing choices can map to claim elements
Because the claims are identity-based (XRD/IR/Raman/DSC), a competitor’s risk is not just the chemical designation “hydrochloride” but the crystal form produced and its hydrate state.
Key risk points:
- crystallization solvent and cooling profile that stabilize the monohydrate
- drying endpoints that fail to fully dehydrate
- milling/grinding and moisture uptake that can transform among polymorphs/hydrates and create the claimed fingerprint
- salt screening and seeding conditions that select Form I
Escape design (claim avoidance pathways, conceptually)
- Switch to a different salt (not hydrochloride) or a non-monohydrate hydrate/solvate.
- Use a different polymorphic form of the hydrochloride that does not match the required XRD/IR/Raman/DSC identity anchors.
- Demonstrate through analytical testing that the accused solid does not meet the claim peak sets within the tolerances.
This is a solid-form patent: the product is defined by measurable patterns, so the “avoidance” strategy is analytic as much as synthetic.
What patent litigation impacts 8,178,550?
No litigation or PTAB/ITC docket information is provided in the prompt. Without court docket data, parties, complaint dates, or settlement details, no accurate litigation-impact analysis can be produced.
How strong is the patent estate for crystalline Form I monohydrate hydrochloride?
Strength signal from claim structure: high enforceability potential for solid-form identification because multiple analytical modalities provide several independent routes to prove infringement:
- XRD anchor (claim 1)
- IR anchor (claim 6)
- Raman anchor (claim 12)
- DSC anchor (claim 18)
- composition claims incorporating the active solid
Strength caveat from claim structure: strong claims can still narrow in practice if:
- “Form I monohydrate hydrochloride” is not coextensive with commercially common lots (e.g., if the market uses slightly different monohydrate batches whose peaks shift beyond tolerances),
- accused solids exhibit partial matches but fail dependent peak-set requirements, or
- figure-based claims (“as shown in FIG. 1/2/3/4”) introduce construction disputes about “substantially as shown” and acceptable variance.
A robust estate usually also includes broader claims (process, intermediate salts, freebase, other forms). None of those additional family members are included in the prompt, so the estate strength assessment is limited to the internal strength of claim 8,178,550.
How does 8,178,550 compare with typical solid-form patents: what does its claim drafting imply?
This patent is drafted as an “identity envelope” around one solid:
- It uses peak position tolerances directly in claim language (±0.2 in 2θ and ±0.04 in Å for XRD; ± tolerances via peak selection lists for IR and Raman implied at the listed frequencies).
- It uses anchor + dependent expansion to create layered fallback coverage.
- It includes orthogonal analytical anchors so proving infringement can be anchored in whichever dataset is strongest for the evidentiary record.
From a freedom-to-operate perspective, this is the blueprint that most commonly survives generic noninfringement attempts because the patentee can present multiple independent analytical confirmations.
Key Takeaways
- US 8,178,550 is a solid-state form patent for crystalline Form I monohydrate hydrochloride of a defined stereospecific diazaspiro compound (Formula I), plus pharmaceutical compositions containing that solid.
- The infringement trigger is analytical identity:
- XRD anchor: 2Θ 21.6 ± 0.2 / 4.11 ± 0.04 Å (claim 1),
- IR anchor: 1167 cm⁻1 (claim 6),
- Raman anchor: 3695 cm⁻1 (claim 12),
- DSC anchor: endotherm ~101°C (claim 18).
- Dependent claims add specificity via additional peak combinations (XRD: 16.1/18.4/23.5; IR: 1693/1277/1141/1130/1094/703/682; Raman: 3690/3625/1604/1032/997/724/616).
- Product claims are not limited to a specific dosage form; they attach to pharmaceutical compositions that use the claimed solid form.
FAQs
1) Does US 8,178,550 cover the freebase (un-salted) form of Formula I?
No. The claims are directed to the hydrochloride monohydrate crystalline Form I defined by XRD/IR/Raman/DSC identities.
2) What XRD peak is the key anchor for claim 1?
A strong peak at 2Θ 21.6 ± 0.2 with lattice spacing 4.11 ± 0.04 Å.
3) Can a manufacturer avoid infringement by using another hydrate form?
In principle, yes, because the claims require the monohydrate and the Form I identity via required spectral/thermal anchors and peak sets.
4) Do the composition claims require a specific formulation excipient?
The provided claims specify a pharmaceutical composition comprising the claimed solid form; no excipient-specific limitation is visible in the claim set excerpt.
5) Are there multiple independent evidentiary routes to prove infringement?
Yes. The claims provide multiple analytical handles: XRD, IR, Raman, and DSC (depending on which claim is asserted).
References
- United States Patent US 8,178,550 (claims provided in prompt).
